Tag - eisai

 
Menu
Search
 
November 22, 2024
 

Today's print edition

Home Delivery
Subscribe for more access

EISAI

Lecanemab was developed by drugmakers Eisai of Japan and Biogen of the United States.
JAPAN / Science & Health
Nov 15, 2024
European agency switches to recommending new Alzheimer's drug
The committee judged that the efficacy of lecanemab outweighs the risk for some patients.
Mecobalamin is a form of vitamin B12 sold as a remedy for peripheral neuropathy and other conditions. It was initially proposed for pharmaceutical approval as a treatment for ALS in 2015 by drugmaker Eisai Co. after its clinical trial found a certain level of efficacy.
JAPAN / Science & Health
Sep 24, 2024
Japan approves sale of new ALS drug, raising hopes among patients
The drug, mecobalamin, extended the survival period of patients within a year of the onset of ALS by over 500 days, surpassing existing drugs.
A scientist looks at brain scans of a patient suffering from Alzheimer's disease in Geneva in 2023.
WORLD / Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
U.K. authorities have approved lecanemab, a novel Alzheimer's drug developed by Eisai, making Britain the first country in Europe to greenlight the drug.
JAPAN
Aug 23, 2024
Britain OKs Eisai's novel Alzheimer's drug lecanemab
The United Kingdom is the first country in Europe to greenlight the drug.
Leqembi, which was developed by U.S. multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab, which is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.
JAPAN / Science & Health
Jul 27, 2024
European medicines watchdog rejects Eisai's new Alzheimer's drug
The watchdog said the risks of side effects, including potential brain bleeding, outweighed the benefits.
A monk practices "zazen" (seated meditation), a practice that the monk Dogen said would help one cast aside the world in service of the Way.
JAPAN / History / The Living Past
May 17, 2024
The joy of Zen — Part 1: Prose
The writings of the monks Eisai and Dogen sought to determine the proper way to live on this Earth, in harmony with the Way.
Tests for patients suffering from Alzheimer's disease. According to the Alzheimer's Association, the disease is estimated to affect more than 6 million Americans.
WORLD / Science & Health / FOCUS
Apr 24, 2024
Alzheimer's drug adoption in U.S. slowed by doctors' skepticism
There is an entrenched belief among some doctors that treating the memory-robbing disease is futile.
Alzheimer's drug lecanemab. A new trial is the world's first to combine lecanemab with a different drug.
JAPAN / Science & Health
Mar 15, 2024
Japan starts clinical trial of familial Alzheimer's treatment
The clinical trial is under way in 16 countries, with four people in their 30s to 50s participating in Japan.
Eisai's Alzheimer's drug Leqembi
BUSINESS / Companies
Feb 5, 2024
Eisai sees 'huge' growth potential for Alzheimer's drug in China
The Japanese pharmaceutical firm aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year.
An elderly person plays a racing video game in 2022 to ward off dementia.
JAPAN / Science & Health
Sep 25, 2023
As Japan OKs Alzheimer's drug, issue of side effects comes into focus
There are big challenges ahead for the use of lecanemab, particularly on how to control side effects such as brain swelling and bleeding.
Packages of lecanemab, marketed as Leqembi, for the U.S. market
JAPAN / Science & Health
Aug 21, 2023
Japanese ministry panel gives OK to Alzheimer’s drug lecanemab
The panel’s endorsement will be followed by official approval by the health minister in coming days.
Japan Times
BUSINESS / Companies
Jul 11, 2023
Eisai appoints CEO’s son to lead global Alzheimer drug program
Eisai's former global Alzheimer drug program officer, who led the push for U.S. approval of breakthrough medicine Leqembi, will retire at the end of the month.
Japan Times
WORLD / Science & Health
Jul 7, 2023
Eisai Alzheimer's drug gets full U.S. approval, widening access to the therapy
The broader clearance from the Food and Drug Administration marks a milestone for treatment of the dementia that afflicts some 6 million Americans.
Japan Times
JAPAN / Science & Health / FOCUS
Jul 4, 2023
Expectations grow for Alzheimer's drug in Japan, but hurdles remain
Lecanemab could be approved in the country as early as fall, but more specialist doctors and a patient screening system would be needed for widespread use.
Japan Times
WORLD / Science & Health
Jun 19, 2023
New Eisai and Biogen Alzheimer drug faces hurdles in Europe
Some doctors said its effect on the disease may not be clinically meaningful enough when weighed against the risk of brain swelling, its likely high price.
Japan Times
JAPAN
Jan 30, 2023
Priority review status given to Alzheimer's drug developed by Eisai and Biogen
The companies said priority review in Japan is granted to new medicines recognized as having high medical utility for serious diseases.
Japan Times
BUSINESS / Markets
Jan 10, 2023
Eisai shares jump after FDA approves Alzheimer’s drug lecanemab
The drug, to be sold under the brand name Leqembi, was approved by the Food and Drug Administration under an accelerated pathway.
Japan Times
JAPAN / Science & Health
Dec 22, 2022
Japan approves blood test to detect Alzheimer’s
Japan has approved one of the world’s first blood test kits to detect signs of Alzheimer’s disease, paving way for a simpler and speedier diagnosis of the ailment for which a therapy is on the horizon.
Two of America’s biggest debt holders are dumping Treasurys
The U.S. Treasury building in Washington. Investors in Japan and China sold a pile of U.S. debt in the last quarter, just before the U.S. presidential election.
Ishiba aggravates his own political failures with diplomatic faux pas
Prime Minster Shigeru Ishiba is greeted at the APEC summit in Lima by Canadian Prime Minister Justin Trudeau on Friday. The Japanese leader was criticized for remaining seated while meeting several world leaders at the event.
Japan's 3.31 million visitors in October set monthly record
Kiyomizu Temple in Kyoto in December 2023. Famous autumn leaf colors contributed to increased tourism demand last month from many markets across Asia, Europe and North America, the Japan National Tourism Organization has said.
Japan ranks last in romance satisfaction for second straight year
In a survey of 31 countries, Japan ranked last in terms of those who felt loved, with just 51% of respondents saying so.
Ruling coalition and DPP strike last-minute deal over economic policy
DPP policy chief Makoto Mahaguchi speaks at the party's policy gathering in Tokyo on Wednesday.
Japan, U.K. and Italy discuss inviting more countries to joint fighter project
A new concept model of a next-generation fighter jet to be jointly developed by Japan, Britain and Italy is on display in Farnborough, Hampshire, in July.
Haruki Murakami's 'The City and Its Uncertain Walls' gives deep deja vu
For “The City and Its Uncertain Walls,” translated into English by Philip Gabriel, Haruki Murakami confronts the ghosts who won't leave him alone.
Japanese expats in Asia find community through rugby
The Taiwan Fivewoods celebrate their victory at the 2023 Asian Japanese Rugby Cup in December of last year.
In Fukushima, a weekend of prose, poetry and translation
Aomori-based writer JJ Carter presented on tabletop gaming as creative inspiration for building characters and narratives.
For Dr. Nakamats, aging is just experience in action
Though he didn't win the recent gubernatorial election in Tokyo, the 96-year-old Dr. Nakamats' run was seen as inspirational in Japan's aging society.

Podcast

One of the many entrances to the Kabukicho neighborhood in Tokyo’s Shinjuku Ward.
Kabukicho: Tokyo’s ‘stadium of desire’

Longform

Construction takes place on the Takanawa Gateway Convention Center in Tokyo, slated to open in 2025.
A boom for business tourism in Japan?
By Kathryn Wortley

SUSTAINABLE JAPAN

SWCC keeps changing with keyword ‘new challenges’
SWCC keeps changing with keyword ‘new challenges’

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER